<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01585051</url>
  </required_header>
  <id_info>
    <org_study_id>x335/08</org_study_id>
    <nct_id>NCT01585051</nct_id>
  </id_info>
  <brief_title>Effect of Vitamin D Supplementation on Blood Pressure and HbA1c Levels in Patients With T2D</brief_title>
  <official_title>Effect of Administration of 25(OH) Vitamin on Mean 24 Hour Blood Pressure and HBA1c Levels in Patients With Stable Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kantonsspital Baselland Bruderholz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kantonsspital Baselland Bruderholz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effect of administration of vitamin D is tested on the long-term control of blood sugar
      (as measured by HbA1-c levels in blood) and mean blood pressure (as measured by 24 hour blood
      pressure profiles)in patients with stable type 2 diabetes mellitus
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HBA1-c levels</measure>
    <time_frame>3 and 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>24 hour mean blood pressure</measure>
    <time_frame>3 and 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>plasma glucose</measure>
    <time_frame>3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HOMA</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Diabetes Mellitus Type 2</condition>
  <arm_group>
    <arm_group_label>vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Intramuscular injection of 300 000 U of 25(OH)vitamin D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>administration of 0.9 % NaCl as a placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>25(OH) vitamin D</intervention_name>
    <description>300 000 U intramuscularly, one dosage, in subjects with 25 (OH) vit D levels below 80 nmol/L, another dosage of 150 000 U after 3 months if 25(OH)vit D levels continue to be below 80 nmol/L.</description>
    <arm_group_label>vitamin D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9 % NaCl</intervention_name>
    <description>1 ml of 0.9 % of NaCl at the beginning and 0.5 ml of 0.9 % NaCl after three months</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Men and women, ages â‰¥18 years

          -  Official diagnostic criteria for type 2 diabetes fulfilled in patients on any type of
             oral or parenteral glucose-lowering treatment

          -  Independent living at home

          -  On stable regimen of BP meds (if any) with BP well controlled and/or K supplement (if
             any) for 2 months and which is deemed unlikely to change during the study

          -  Stable glucose control for 2 months by any approved method including insulin

        Exclusion criteria

          -  Patients with type 1 diabetes (or insulin-requiring diabetes of unclear type)

          -  Patients on hemodialysis, with hyperparathyroidism or active cancer disease

          -  Patients with known metabolic bone disease

          -  Laboratory evidence of kidney (eGFR &lt; 60 ml/min) or liver disease

          -  Dietary calcium intake exceeding 1500mg/d (as estimated by dietary history)

          -  25(OH) vitamin D levels at baseline &gt; 70 nmol/L

          -  Calciuria (&gt; 8 mmol/24 hours as measured by 24 hour urine collections)

          -  Hypo- and hypercalcemias and hypo- and hyperphosphatemias of any cause

          -  Medications that affect vitamin D metabolism (e.g. antiepileptic drugs, calcimimetics,
             1-34 PTH (Forsteo) vitamin D therapy over and above 400U daily 6 months prior to
             enrollment and during the study)

          -  Foreseeable need for adaptation of either glucose- or blood pressure lowering during
             the next 6 months as decided by the family physician or the treating diabetologist -
             see above

          -  History of binge eating or wt gain or loss exceeding 6 kg in past 18 months

          -  Patients on any type of inhibitors of plasma coagulation (i.e. coumarine, heparins)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reto Krapf, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine, Kantonsspital Bruderholz, University of Basel, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of medicine, Kantonsspital Bruderholz</name>
      <address>
        <city>Bruderholz/Basel</city>
        <state>Basel-Landschaft</state>
        <zip>CH-4101</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2012</study_first_submitted>
  <study_first_submitted_qc>April 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2012</study_first_posted>
  <last_update_submitted>April 24, 2012</last_update_submitted>
  <last_update_submitted_qc>April 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kantonsspital Baselland Bruderholz</investigator_affiliation>
    <investigator_full_name>Reto Krapf</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>vitamin D</keyword>
  <keyword>blood pressure</keyword>
  <keyword>typ 2 diabetes mellitus</keyword>
  <keyword>blood glucose</keyword>
  <keyword>HbA1c</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

